Poster Session A
Reproductive health
SABRINA HAMROUN, MMed
Rheumatology Department, University Hospital of Cochin, Paris
Paris, France
No financial relationships with ineligible companies to disclose
This study found an increased risk of preterm delivery in RA patients compared with control women in the French general population, which is consistent with an increased risk observed in other countries. These results raise the need for particular attention to obstetrical follow-up in these patients and providing useful insights for physician-patient dialogue.
Table 1. Matched comparative analysis of adverse fetal, maternal and pregnancy outcomes in RA patients (GR2 cohort) and control women of the French general population (2016 and 2021 French national perinatal surveys).
S. Hamroun: None; G. Martin De Frémont: None; N. Costedoat-chalumeau: Bristol-Myers Squibb(BMS), 1; M. couderc: None; R. Flipo: AbbVie/Abbott, 2, Bristol-Myers Squibb(BMS), 2, Eli-Lilly, 2, Fresenius kabi, 7, Galapagos, 7, Janssen-Cilag, 2, Lilly, 7, Medac, 7, MSD, 2, Nordic Pharma, 2, Novartis, 2, Pfizer, 2, Roche-Chugaï, 2, Sandoz, 2; L. Gossec: AbbVie, 2, 5, Amgen, 2, Biogen, 5, Bristol-Myers Squibb (BMS), 2, Celltrion, 2, Eli Lilly, 2, 5, Galapagos, 2, Janssen, 2, MSD, 2, Novartis, 2, 5, Pfizer, 2, Sandoz, 2, UCB, 2, 5; C. Richez: None; R. Belkhir: None; A. Frazier: None; V. Devauchelle: AbbVie, 2, BMS, 2, 5, Chugai, 5, Galapagos, 2, Janssen, 2, Lilly, 2, 5, Novartis, 2, Pfizer, 2; H. Marotte: AbbVie/Abbott, 4, 5, 6, Biogen, 5, 6, Bristol-Myers Squibb(BMS), 5, 6, Celltrion Healthcare, 5, 6, Eli Lilly, 5, 6, Fresenius Kabi, 5, 6, Galapagos, 5, 6, Janssen, 5, 6, Merck/MSD, 5, 6, Nordic Pharma, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, Roche, 5, 6, Sanofi, 5, 6; J. Sellam: AbbVie/Abbott, 7, Bristol-Myers Squibb(BMS), 7, Fresenus kabi, 7, Galapagos, 7, Grunenthal, 7, MSD, 7, Nordic Pharma, 7, Novartis, 7, Pfizer, 7; E. Gervais: None; A. Deroux: None; C. Lukas: None; E. Dernis: AbbVie/Abbott, 2, Amgen, 2, Boehringer-Ingelheim, 2, Celgene, 2, Eli Lilly, 2, Galapagos, 2, Gilead, 2, Janssen, 2, Merck/MSD, 2, Nordic Pharma, 2, Novartis, 2, Pfizer, 2, Roche, 2, roche-chugaï, 2, Sandoz, 2, Sanofi, 2, UCB, 2; E. Chatelus: None; V. Le Guern: None; G. Guettrot-Imbert: None; N. Lelong: None; C. Le Ray: None; R. Seror: Amgen, 6, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Pfizer, 6, Roche, 6; A. Molto: AbbVie, 2, 5, MSD, 2, 5, Pfizer, 2, 5, UCB, 2, 5.